Janus kinase (JAK) inhibitors, including ruxolitinib cream and abrocitinib, demonstrate strong efficacy in atopic dermatitis ...

Sitryx initiates Phase 1 clinical trial of potential disease-modifying treatment for atopic dermatitis SYX-5219 SYX-5219 is a ...

Atopic dermatitis highlights from AAD 2025 include phase 3 trial results on rocatinlimab and delgocitinib, findings on tapinarof 1% cream, and early dosing data on a new JAK1/TYK2 inhibitor.

In a video interview with Healio, Benjamin N. Ungar, MD, discussed the risk factors of atopic dermatitis and the comorbidities associated with the condition.

Robert Sidbury MD, MPH explored the “long list” of treatment options in atopic dermatitis and how the treatment landscape has changed as a result in a video interview with Healio.“So long list – I ...

Bubble baths might be soothing soaks, but bubble showers could be the next thing in keeping the skin clean. An Osaka ...

and TOKYO, March 8, 2025 /PRNewswire/ -- Amgen (NASDAQ ... in moderate to severe atopic dermatitis (AD). The IGNITE study, which evaluated two dose strengths of rocatinlimab, met its co-primary ...

Dr. Jan Dutz, Skin Centre, Vancouver, BC, talks about what Atopic Dermatitis is, it's symptoms and how it is diagnosed. Elon Musk goes behind-the-scenes at DOGE, unveils biggest source of fraud ...

A medical research team has confirmed that ultrafine bubble showers significantly suppress inflammation in mice with atopic dermatitis due to external factors.

A first-of-a-kind therapy that inhibits a population of T cells proved active and safe in a phase 3 trial for moderate to ...